GSE180951 2 V 3 BLEOMYCIN MOUSE UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE180951 2 V 3 BLEOMYCIN MOUSE UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE180951 2 V 3 BLEOMYCIN MOUSE UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE180951 2 V 3 BLEOMYCIN MOUSE UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE180951 2 V 3 BLEOMYCIN MOUSE UP.

Results found

Linked to

 

Label

Description

 

Gene

interleukin 9 receptor

Gene

SUMO specific peptidase 1

Gene

phosphoinositide-3-kinase regulatory subunit 6

Gene

hook microtubule tethering protein 3

Gene

heparan sulfate-glucosamine 3-sulfotransferase 4

Gene

pre-mRNA processing factor 40B

Gene

ribosomal protein S6 kinase like 1

Gene

ankyrin repeat domain 2

Gene

ubiquitin like with PHD and ring finger domains 2

Gene

hydroxyacid oxidase 2

  • Gene

    interleukin 9 receptor


  • Gene

    SUMO specific peptidase 1


  • Gene

    phosphoinositide-3-kinase regulatory subunit 6


  • Gene

    hook microtubule tethering protein 3


  • Gene

    heparan sulfate-glucosamine 3-sulfotransferase 4


  • Gene

    pre-mRNA processing factor 40B


  • Gene

    ribosomal protein S6 kinase like 1


  • Gene

    ankyrin repeat domain 2


  • Gene

    ubiquitin like with PHD and ring finger domains 2


  • Gene

    hydroxyacid oxidase 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.